WGPlus (Archive)

A major health issue of growing importance

The European Medicines Agency (EMA) is informing about a potential increased risk of lower limb amputation (mostly affecting the toes) in patients taking the SGLT2 inhibitors canagliflozin, dapagliflozin and empagliflozin used for type 2 diabetes.

Patients taking these medicines are reminded to check their feet regularly and follow their doctor’s advice on routine preventative foot care. They should also tell their doctor if they notice any wounds or discoloration, or if their feet are tender or painful.

The review of SGLT2 inhibitors was prompted by an increase in lower limb amputations (mostly affecting the toes) in patients taking canagliflozin in two clinical trials, CANVAS and CANVAS-R.  The studies, which are still ongoing, involved patients at high risk of heart problems and compared canagliflozin with placebo (a dummy treatment).
Researched Links:

EU News:  Diabetes patients reminded of importance of preventative foot care

DH:  Warm welcome for UK diabetes prevention programme in Dubai

NHS England:  Collaboration is key to the diabetes model of care

Equivalent to more than the whole population of Scotland

Emotional support required as well as medical

Proactive healthcare in the community is cheaper than surgery